Showing 1 - 20 of 83 Items
Showing 1 - 20 of 83 Items
Sort By: Relevance
Journal Article
|Letter
2025-04-04 • Lancet Infectious Diseases
2025-04-04 • Lancet Infectious Diseases
Journal Article
|Research
2025-01-08 • Lancet Infectious Diseases
2025-01-08 • Lancet Infectious Diseases
BACKGROUND
Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis, particularly in Asia and Africa, where HEV genotypes 1 and 2 are prevalen...
Journal Article
|Research
2025-01-08 • Lancet Infectious Diseases
2025-01-08 • Lancet Infectious Diseases
BACKGROUND
In settings with low pneumococcal conjugate vaccine (PCV) coverage, multi-age cohort mass campaigns could increase population immunity, and fractiona...
Journal Article
|Review
2024-12-12 • Lancet Infectious Diseases
2024-12-12 • Lancet Infectious Diseases
Journal Article
|Review
2024-12-01 • Lancet Infectious Diseases
2024-12-01 • Lancet Infectious Diseases
The west Africa Ebola disease epidemic (2014-16) marked a historic change of course for patient care during emerging infectious disease outbreaks. The epidemic response was a failure ...
Journal Article
|Research
2024-09-01 • Lancet Infectious Diseases
2024-09-01 • Lancet Infectious Diseases
BACKGROUND
Lassa fever is a viral haemorrhagic fever with few options for diagnosis and treatment; it is also under-researched with knowledge gaps on its epidemiology. A point-of-car...
Lassa fever is a viral haemorrhagic fever with few options for diagnosis and treatment; it is also under-researched with knowledge gaps on its epidemiology. A point-of-car...
Journal Article
|Case Report/Series
2024-08-01 • Lancet Infectious Diseases
2024-08-01 • Lancet Infectious Diseases
BACKRGOUND
The rec...
Journal Article
|Commentary
Accumulating evidence on the long-term immunogenicity of fractional dosing for yellow fever vaccines
2024-06-01 • Lancet Infectious Diseases
2024-06-01 • Lancet Infectious Diseases
Journal Article
|Letter
2024-04-30 • Lancet Infectious Diseases
2024-04-30 • Lancet Infectious Diseases
Journal Article
|Research
2024-02-01 • Lancet Infectious Diseases
2024-02-01 • Lancet Infectious Diseases
BACKGROUND
The rVSVΔG-ZEBOV-GP vaccine constitutes a valuable tool to control Ebola virus disease outbreaks. This retrospective cohort study aimed to assess the protective effect of ...
The rVSVΔG-ZEBOV-GP vaccine constitutes a valuable tool to control Ebola virus disease outbreaks. This retrospective cohort study aimed to assess the protective effect of ...
Journal Article
|Review
2024-01-01 • Lancet Infectious Diseases
2024-01-01 • Lancet Infectious Diseases
For the past 15 years, trials of combination therapy options for visceral leishmaniasis have been conducted with the aim of identifying effective, and safe treatment regimens that were s...
Journal Article
|Commentary
2023-08-18 • Lancet Infectious Diseases
2023-08-18 • Lancet Infectious Diseases
Journal Article
|Research
2023-04-28 • Lancet Infectious Diseases
2023-04-28 • Lancet Infectious Diseases
BACKGROUND
Current supply shortages constrain yellow fever vaccination activities, particularly outbreak response. Although fractional doses of all WHO-prequalified yellow fever vacc...
Current supply shortages constrain yellow fever vaccination activities, particularly outbreak response. Although fractional doses of all WHO-prequalified yellow fever vacc...
Journal Article
|Commentary
2023-04-24 • Lancet Infectious Diseases
2023-04-24 • Lancet Infectious Diseases
Journal Article
|Commentary
2023-04-01 • Lancet Infectious Diseases
2023-04-01 • Lancet Infectious Diseases
Journal Article
|Letter
2023-04-01 • Lancet Infectious Diseases
2023-04-01 • Lancet Infectious Diseases
Journal Article
|Research
2023-03-01 • Lancet Infectious Diseases
2023-03-01 • Lancet Infectious Diseases
BACKGROUND
Tuberculosis diagnosis might be delayed or missed in children with severe pneumonia because this diagnosis is usually only considered in cases of prolonged symptoms or ant...
Tuberculosis diagnosis might be delayed or missed in children with severe pneumonia because this diagnosis is usually only considered in cases of prolonged symptoms or ant...
Journal Article
|Commentary
2023-01-19 • Lancet Infectious Diseases
2023-01-19 • Lancet Infectious Diseases
Three years since proving effective for Ebola virus disease in a clinical trial, two breakthrough treatments are registered and stockpiled in the USA but still not registered and general...
Journal Article
|Research
2023-01-01 • Lancet Infectious Diseases
2023-01-01 • Lancet Infectious Diseases
BACKGROUND
In its earliest phases, Ebola virus disease's rapid-onset, high fever, and gastrointestinal symptoms are largely indistinguishable from other infectious illnesses. We aime...
In its earliest phases, Ebola virus disease's rapid-onset, high fever, and gastrointestinal symptoms are largely indistinguishable from other infectious illnesses. We aime...
Journal Article
|Letter
2022-08-01 • Lancet Infectious Diseases
2022-08-01 • Lancet Infectious Diseases